Advertisement
DHR vs TMO
Which Stock Would AI Choose? Danaher (DHR) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Danaher (DHR) and Thermo Fisher Scientific (TMO) both operate in the life sciences tools and diagnostics sector, with exposure to biotechnology, pharmaceuticals, and diagnostics end markets.
- In recent market activity, TMO reported stronger year-over-year revenue growth and raised its full-year 2026 organic growth outlook following robust Q2 results.
- DHR completed a significant acquisition of Masimo in June 2026 and announced a quarterly dividend in mid-September 2026, while navigating moderating core growth trends.
- TMO has demonstrated higher recent momentum with organic revenue growth of 5% in Q2 2026 and broad-based demand recovery across pharma and biotech segments.
- Both companies emphasize recurring revenue streams from consumables and services, though TMO maintains a larger scale with market capitalization exceeding $240 billion compared to DHR’s approximately $149 billion.
- Market sentiment reflects contrasting positioning, with TMO benefiting from raised guidance and DHR focusing on integration and operational discipline amid mixed growth signals.
Introduction
Danaher (DHR) and Thermo Fisher Scientific (TMO) represent two leading players in the life sciences and diagnostics industry, making them natural subjects for comparison among investors and traders seeking exposure to healthcare tools and technology. Both firms supply instruments, consumables, and services critical to drug discovery, development, and production, with substantial recurring revenue components that provide relative stability. This comparison appeals to growth-oriented investors monitoring sector recovery, momentum traders evaluating relative performance, and portfolio managers assessing diversification within healthcare. In the current environment of improving end-market demand and evolving macroeconomic conditions, understanding their distinct business models, recent results, and positioning helps clarify potential trade-offs between scale, growth drivers, and risk profiles.
DHR Overview and Recent Performance
Danaher Corporation (DHR) delivers life sciences, diagnostics, and biotechnology solutions through a portfolio emphasizing the Danaher Business System for operational efficiency. In recent weeks, the stock has traded near $212, reflecting modest one-month changes alongside stronger three-month gains. Q2 2026 results showed revenue of $6.3 billion, up 5.5% year-over-year, with non-GAAP core revenue growth of 3% and 4.5% excluding respiratory testing. The company completed its Masimo acquisition in June 2026 for approximately $9.8 billion, contributing to raised full-year adjusted earnings guidance. Recent market activity includes a quarterly dividend declaration of $0.40 per share in mid-September 2026 and leadership transition with a new CEO appointment in August. Sentiment has been influenced by integration progress offset by notes of moderating organic demand in certain segments.
TMO Overview and Recent Performance
Thermo Fisher Scientific (TMO) provides analytical instruments, laboratory products, specialty diagnostics, and biopharma services on a global scale. Recent performance shows the stock around $651, with notable year-to-date and one-year appreciation exceeding 35% in some measures. Q2 2026 delivered revenue of $11.99 billion, up 10% year-over-year, including 5% organic growth that surpassed prior expectations. Management raised full-year 2026 guidance, citing strengthening customer activity across pharma, biotech, and industrial markets. Additional developments include share repurchases totaling $1 billion in the quarter and plans to divest the microbiology business. Broader sentiment has benefited from consistent execution and portfolio optimization, supporting relative outperformance versus peers in recent market activity.
Trending AI Robots
Tickeron maintains a curated Trending AI Robots section that highlights select AI trading bots from its extensive library of hundreds of bots capable of trading thousands of tickers. Only those demonstrating strong suitability for prevailing market conditions earn placement in this trending roster, which showcases varied trading styles, strategies, timeframes, performance metrics, and ticker sets. Available bots feature a wide range of statistics, including win rates, profit factors, and drawdown profiles that can span from conservative low-volatility approaches to more aggressive momentum-driven systems. This diversity allows traders to explore options aligned with different risk tolerances and market views. Review the Trending AI Robots page for current selections and detailed performance data.
Head-to-Head Comparison
Danaher (DHR) and Thermo Fisher Scientific (TMO) share life sciences sector exposure but differ in scale and emphasis. TMO operates at larger revenue and market capitalization levels, with broader instrument and services offerings that support higher organic growth rates in recent quarters. DHR leverages a decentralized operating model and recent acquisition activity for portfolio expansion, though it has faced more tempered core growth signals. Momentum favors TMO following its raised guidance and demand recovery, while DHR offers dividend income and integration-driven earnings support. Risk factors include acquisition integration for DHR and potential valuation pressures for TMO amid its stronger recent run. Both benefit from recurring revenue but exhibit trade-offs in growth consistency versus operational discipline.
Tickeron AI Verdict
Based on observable factors such as recent organic growth consistency, guidance momentum, and end-market positioning, Tickeron’s AI models would currently assign a higher probabilistic preference to Thermo Fisher Scientific (TMO) over Danaher (DHR). TMO’s stronger Q2 results and raised outlook reflect more favorable trend alignment in the near term, though DHR’s acquisition integration and dividend stability provide counterbalancing elements that could narrow the gap depending on upcoming data.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Disclaimers and LimitationsDHR and TMO are companies in the life sciences and diagnostics sector of healthcare, but DHR has historically been more diversified in terms of the services it provides and industries. In recent years, it has separated itself from certain subsidiaries. The companies have been on a wild ride throughout the pandemic, with promising opportunities to play a role in the battle against the virus, but they have also shared in the uncertainty and struggles that other industries have been due to closures. Both have done extremely well in recent quarters providing life science products and solutions to the healthcare industry and governments. DHR made two extremely profitable acquisitions just prior to the pandemic that put it in a prime position for revenue growth; namely Cepheid, which has churned out Covid test kits, and Cytiva, which used to be GE’s biopharma subsidiary. They are now extremely similar in size and function. Both are likely to remain indispensable in the new healthcare landscape for several years.
DHR | TMO | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 79 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 8 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 72 | |
SMR RATING 1..100 | 77 | 60 | |
PRICE GROWTH RATING 1..100 | 54 | 20 | |
P/E GROWTH RATING 1..100 | 50 | 20 | |
SEASONALITY SCORE 1..100 | n/a | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
DHR's Valuation (8) in the Medical Specialties industry is in the same range as TMO (13). This means that DHR’s stock grew similarly to TMO’s over the last 12 months.
TMO's Profit vs Risk Rating (72) in the Medical Specialties industry is in the same range as DHR (100). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as DHR (77). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
TMO's Price Growth Rating (20) in the Medical Specialties industry is somewhat better than the same rating for DHR (54). This means that TMO’s stock grew somewhat faster than DHR’s over the last 12 months.
TMO's P/E Growth Rating (20) in the Medical Specialties industry is in the same range as DHR (50). This means that TMO’s stock grew similarly to DHR’s over the last 12 months.
| DHR | TMO | |
|---|---|---|
| RSI ODDS (%) | 3 days ago 39% | 3 days ago 55% |
| Stochastic ODDS (%) | 3 days ago 62% | 3 days ago 56% |
| Momentum ODDS (%) | 3 days ago 61% | 3 days ago 70% |
| MACD ODDS (%) | 3 days ago 65% | 3 days ago 63% |
| TrendWeek ODDS (%) | 3 days ago 57% | 3 days ago 62% |
| TrendMonth ODDS (%) | 3 days ago 57% | 3 days ago 62% |
| Advances ODDS (%) | 9 days ago 55% | 7 days ago 62% |
| Declines ODDS (%) | 13 days ago 61% | 16 days ago 62% |
| BollingerBands ODDS (%) | 3 days ago 64% | 3 days ago 56% |
| Aroon ODDS (%) | 3 days ago 57% | 3 days ago 59% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
DHR’s FA Score shows that 1 FA rating(s) are green while TMO’s FA Score has 3 green FA rating(s).
- DHR’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 3 green, 2 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
DHR’s TA Score shows that 6 TA indicator(s) are bullish while TMO’s TA Score has 5 bullish TA indicator(s).
- DHR’s TA Score: 6 bullish, 4 bearish.
- TMO’s TA Score: 5 bullish, 4 bearish.
Price Growth
DHR (@Medical Specialties) experienced а +6.19% price change this week, while TMO (@Medical Specialties) price change was +7.44% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was +5.02%. For the same industry, the average monthly price growth was +3.27%, and the average quarterly price growth was +48.78%.
Reported Earning Dates
DHR is expected to report earnings on Oct 27, 2026.
TMO is expected to report earnings on Oct 28, 2026.
Industries' Descriptions
@Medical Specialties (+5.02% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
DHR and
Correlation & Price change
A.I.dvisor indicates that over the last year, DHR has been closely correlated with TMO. These tickers have moved in lockstep 77% of the time. This A.I.-generated data suggests there is a high statistical probability that if DHR jumps, then TMO could also see price increases.
| Ticker / NAME | Correlation To DHR | 1D Price Change % | ||
|---|---|---|---|---|
| DHR | 100% | +1.90% | ||
| TMO - DHR | 77% Closely correlated | +1.12% | ||
| A - DHR | 73% Closely correlated | +3.50% | ||
| RGEN - DHR | 68% Closely correlated | +2.16% | ||
| BIO - DHR | 64% Loosely correlated | +0.24% | ||
| BRKR - DHR | 58% Loosely correlated | +0.39% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | +1.12% | ||
| A - TMO | 74% Closely correlated | +3.50% | ||
| DHR - TMO | 73% Closely correlated | +1.90% | ||
| RVTY - TMO | 70% Closely correlated | +0.10% | ||
| IQV - TMO | 69% Closely correlated | +1.30% | ||
| BRKR - TMO | 67% Closely correlated | +0.39% | ||
More | ||||